Q-omics provides the consensus-scored KCTD12 profile across patient tissues and cancer cell-line models. KCTD12 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, KCTD12 is differentially expressed in 13, with the highest sampling consensus in LUAD. Additionally, KCTD12 protein abundance shows 29,569 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LUAD, and LSCC as cancer lineages where KCTD12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCTD12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCTD12 survival associations across molecular data types. KCTD12 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCTD12 RNA expression–survival associations across cancer types. High KCTD12 expression shows unfavorable associations in UVM, LGG, LAML and UCEC, but favorable associations in LUAD and KIRC. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for KCTD12 RNA expression.
This table summarizes KCTD12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in LUAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for KCTD12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCTD12 shows lower tumor expression in LUAD, COAD, KIRC, LUSC, BLCA and UCEC. The LUAD box plot shows higher KCTD12 RNA expression in normal versus tumor tissue (log2 FC = −1.766, t-test p < 0.001).
This table shows molecular features associated with KCTD12 in patient tissues and cancer cell lines. In patient samples, KCTD12 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, KCTD12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BREAST.
